Phase 2 Lung Cancer Trial, Recruiting NCT06589778 Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06589778
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are willing and able to give informed consent, understand the study, and are able to follow all study procedures to completion.
  • People aged between 18 and 70 years old.
  • People who have been diagnosed through laboratory testing with non-small cell lung cancer that cannot be removed by surgery and has either spread locally or to other parts of the body.
  • People who have at least one tumour that can be measured using standard imaging criteria (known as RECIST v1.1).
  • People whose general health and ability to carry out daily activities falls within a certain range, rated as 0 or 1 on a standard scale used by doctors (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have cancer that has spread to the brain and is currently active or causing symptoms.
  • People who have previously been diagnosed with any other type of cancer.
  • People who have a significant build-up of fluid in the abdomen that is causing symptoms, or fluid around the lungs or heart that cannot be controlled or is moderate to severe.
  • People who have received any cancer treatment within the 4 weeks before the study treatment would begin.
  • People who have cancer-related pain that cannot be controlled.
  • People who have serious heart or blood vessel conditions (confirm with trial site for specific conditions).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

Contact this trial

Phone: 0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
27 September 2024
Est. completion
30 April 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Determination of Recommended Phase II dose (RP2D); Objective Response Rate (ORR); Incidence and severity of AEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov